Mylan Launches Generic Nor-Q.D.® Tablets, 0.35 mg (28-Day Cycle)
July 16, 2013 at 11:44 AM EDT
Mylan Inc. (Nasdaq: MYL ) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Norethindrone Tablets USP, 0.35 mg. Norethindrone Tablets USP, 0.35 mg, are the generic version of Watson Laboratories' (now Actavis, Inc.) Nor-Q.D.® Tablets, 0.35 mg (28-Day Cycle), which are indicated for the prevention of
